Sequana Medical NV
(Euronext Brussels: SEQUA, the Company or Sequana Medical ), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces positive results from the second interim analysis of POSEIDON, the North American pivotal study of the
alfapump for the treatment of recurrent or refractory ascites due to liver cirrhosis. These interim data from 26 patients in the Roll-In Cohort are in line with the previous interim data
ii, including positive outcomes against all primary endpoints of the study and a rapid and persistent clinically important improvement in quality of life measures.
Sequana Medical NV: Sequana Medical announces positive results from second interim analysis of North American pivotal alfapump study (POSEIDON)
i
All patients experienced
Safety
Primary endpoint read-out
Sequana Medical NV
(Euronext Brussels: SEQUA, the Company or Sequana Medical ), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces positive results from the second interim analysis of POSEIDON, the North American pivotal study of the
alfapump for the treatment of recurrent or refractory ascites due to liver cirrhosis. These interim data from 26 patients in the Roll-In Cohort are in line with the previous interim data